Skip to main content

PI3K/PTEN-related monogenic disease to understand cancer

Objective

There are more than 7000 rare diseases, affecting approximately 30 million European Union citizens. Eighty percent of rare diseases have monogenic origin and are often chronic or life-threatening. Several of these genetic mutations are also implicated in cancer, a disease of epidemic proportions (>14 million new cases/year worldwide). Genetic alterations in the PI3K/PTEN pathway are common events in both monogenic rare diseases and in cancer. Despite the molecular commonalities, these two pathologies have predominantly been investigated as independent entities. We aim to take advantage of the knowledge that has been generated regarding the role of PI3K in cancer to better understand the recently-discovered PI3K-related rare diseases (overgrowth syndromes, primary immunodeficiencies and cognitive deficiencies). Conversely, discoveries emanating from PI3K-related rare diseases will impact in the understanding of cancer. Ultimately, this cross-fertilization will impact on the clinical strategies to treat both rare diseases and cancer. Our network, under the acronym of PIPgen, aims to (1) produce the next generation of scientists that can navigate with ease between academic, industrial and clinical sectors and have the scientific and softs skills to convert research findings into commercialization and clinical applications, and (2) generate innovative knowledge that can be translated to the diagnosis and treatment of both rare diseases and cancer. This network provides a pan-European interdisciplinary and intersectorial training program of excellence bringing young researchers together with world leading academics, clinicians, entrepreneurs with experience from the pharma industry, corporate research as well as with dissemination and outreach activities. PIPgen has been conceived to make a real therapeutic impact both in rare diseases and cancer, based on basic bioscience.

Call for proposal

H2020-MSCA-ITN-2020
See other projects for this call

Coordinator

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Address
Carretera De Can Ruti Sn Campus Ico Germans Trias I Pujol/uab
08916 Badalona
Spain
Activity type
Research Organisations
EU contribution
€ 501 809,76

Participants (10)

UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 606 345,12
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 549 604,08
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 606 345,12
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DE PARIS
France
EU contribution
€ 274 802,04
Address
85 Bd Saint Germain
75006 Paris
Activity type
Higher or Secondary Education Establishments
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 265 619,88
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
STICHTING VUMC
Netherlands
EU contribution
€ 265 619,88
Address
De Boelelaan 1117
1081 HV Amsterdam
Activity type
Research Organisations
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands
EU contribution
€ 265 619,88
Address
Geert Grooteplein 10 Zuid
6525 GA Nijmegen
Activity type
Higher or Secondary Education Establishments
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Spain
EU contribution
€ 250 904,88
Address
Parque Tecnologico Edificio 801 A
48160 Derio Vizcaya
Activity type
Research Organisations
KITHER BIOTECH SRL
Italy
EU contribution
€ 261 499,68
Address
Via Nizza 52
10126 Torino
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
QUANTITATIVE GENOMIC MEDICINE LABORATORIES SL
Spain
EU contribution
€ 250 904,88
Address
Calle Joan Xxiii 10
08950 Esplugues Del Llobregat
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)